

Orthobiologics Market Forecasts to 2032 – Global Analysis By Product Type (Bone Grafts, Growth Factors, Platelet-Rich Plasma (PRP), Stem Cells, Cell-Based Therapies and Other Product Types), Distribution Channel, Application, End User and By Geography

<https://marketpublishers.com/r/O23FCD09523AEN.html>

Date: April 2025

Pages: 150

Price: US\$ 4,150.00 (Single User License)

ID: O23FCD09523AEN

Abstracts

According to Statistics MRC, the Global Orthobiologics Market is accounted for \$7.2 billion in 2025 and is expected to reach \$11.2 billion by 2032 growing at a CAGR of 6.5% during the forecast period. Orthobiologics is the use of biological materials and substances to promote healing and repair in musculoskeletal conditions. These therapies include stem cells, platelet-rich plasma (PRP), growth factors, and extracellular matrix proteins, which are derived from the body or synthesized. Orthobiologics are often used in orthopedics to treat injuries or degenerative diseases by stimulating tissue regeneration, reducing inflammation, and accelerating healing processes. This approach offers a more natural alternative to surgery, with the potential for improved outcomes and reduced recovery times for patients with joint, ligament, tendon, or bone injuries.

According to the ISAPS Global Survey, the number of procedures performed by plastic surgeons increased by 11.2% in 2022. About 18.8 million non-surgical and 14.9 million surgical procedures were performed worldwide, continuing the trend of a 41.3% increase over the last four years.

Market Dynamics:

Driver:

Growing demand for minimally invasive procedures

The growing demand for minimally invasive procedures in the market is driven by their ability to offer faster recovery times, reduced risk of complications, and less post-operative pain compared to traditional surgeries. Patients increasingly prefer these procedures due to their effectiveness in treating musculoskeletal injuries with minimal disruption to surrounding tissues. As technologies improve and awareness rises, the adoption of minimally invasive Orthobiologic treatments like PRP and stem cell therapies is expected to continue growing, transforming the landscape of orthopedic care.

Restraint:

Lack of standardization

The lack of standardization in the market poses significant challenges, including inconsistent treatment outcomes and safety concerns. Without clear guidelines, the quality and efficacy of therapies like stem cell injections and platelet-rich plasma (PRP) can vary widely, leading to unpredictable results for patients. This inconsistency undermines patient trust and can hinder widespread adoption. Additionally, the absence of standardized protocols complicates regulatory oversight, increasing the risk of unproven or unsafe treatments entering the market and potentially harming patients.

Opportunity:

Rising awareness of regenerative medicine

Rising awareness of regenerative medicine is significantly influencing the market, as patients and healthcare providers recognize its potential for healing and tissue repair. Regenerative treatments, such as stem cell therapy and platelet-rich plasma (PRP), offer promising alternatives to traditional surgeries, addressing musculoskeletal injuries and degenerative conditions. As education and research advance, more people are seeking out these innovative treatments for faster recovery and improved outcomes. This growing awareness is driving the increasing demand and expansion of regenerative medicine in orthobiologic applications.

Threat:

High cost of treatments

The high cost of treatments in the market limits access to these advanced therapies for many patients, particularly those without adequate insurance coverage. Expensive procedures like stem cell therapy or platelet-rich plasma (PRP) injections can be financially burdensome, leading some individuals to forgo potentially beneficial treatments. This not only creates inequities in healthcare access but also slows the widespread adoption of Orthobiologics, as patients may opt for more affordable, conventional treatments, even if they may not offer the same regenerative benefits.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the market by disrupting supply chains, delaying elective procedures, and limiting patient access to treatments. Many orthopedic clinics and hospitals paused non-emergency services, leading to a reduction in the demand for regenerative therapies like stem cell treatments and PRP injections. Additionally, financial constraints and concerns over infection risks led patients to delay or forgo treatments. However, the pandemic also accelerated interest in minimally invasive and non-surgical options, which may drive future growth in the market.

The lumbar fusion segment is expected to be the largest during the forecast period

The lumbar fusion segment is expected to account for the largest market share during the forecast period such as bone grafts or stem cells, to promote the healing and fusion of vertebrae in the lower back. By integrating orthobiologic therapies, lumbar fusion aims to enhance healing, reduce complications, and improve patient outcomes. As minimally invasive techniques gain traction, the demand for regenerative treatments in spinal surgery is expected to increase, offering better recovery options for patients.

The dental clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the dental clinics segment is predicted to witness the highest growth rate. These biologic therapies help accelerate tissue regeneration, reduce inflammation, and improve the overall success of dental surgeries. As awareness of regenerative medicine grows, more dental professionals are integrating Orthobiologics into their practice, providing patients with advanced, minimally invasive options for faster recovery and better long-term results, boosting the demand within the dental sector.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to increasing healthcare awareness. Countries like Japan, China, and India are seeing greater adoption of treatments such as stem cell therapy, platelet-rich plasma (PRP), and bone grafts. Growing healthcare infrastructure, along with a shift towards minimally invasive procedures, is driving demand for Orthobiologics. The market is also supported by improving regulatory frameworks and increasing investments in medical research and technology.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR. Technological advancements in regenerative medicine, including stem cell therapies, gene therapies, and platelet-rich plasma (PRP) treatments, have boosted the efficacy of orthobiologic treatments. These innovations have led to greater adoption among both patients and healthcare providers. Moreover, As more patients and healthcare professionals learn about the benefits of orthobiologic therapies, such as accelerated healing and reduced dependency on traditional drugs or surgeries, demand for these treatments has risen.

Key players in the market

Some of the key players in Orthobiologics Market include Bioventus LLC, Nuvasive, Inc., Anika Therapeutics, Inc., Alphatec Spine, Inc., Medtronic plc, Stryker Corporation, Globus Medical, Inc., Xtant Medical Holdings, Inc., Sanofi S.A., Orthofix Medical Inc., Bone Therapeutics SA, RTI Surgical, Inc. , Kuros Biosciences Ltd. , Smith & Nephew plc, Integra LifeSciences Holdings Corporation , Seaspine Holdings Corporation and Arthrex, Inc.

Key Developments:

In March 2025, Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted

phagocytosis..

In March 2024, Stryker announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space, to create a newly formed company called VB Spine, LLC.

Product Types Covered:

Bone Grafts

Growth Factors

Platelet-Rich Plasma (PRP)

Stem Cells

Cell-Based Therapies

Other Product Types

Distribution Channels Covered:

Direct Sales

Indirect Sales

E-Commerce Platforms

Applications Covered:

Cervical Fusion

Lumbar Fusion

Thoracic Fusion

Hip Replacement

Shoulder Reconstruction

Dental Implants

Wound Healing

Microfracture Surgery

Ligament Repair

Other Applications

End Users Covered:

Hospitals

Ambulatory Surgical Centers

Orthopedic Clinics

Dental Clinics

Rehabilitation Centers

Research Institutes

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Product Analysis
- 3.7 Application Analysis
- 3.8 End User Analysis
- 3.9 Emerging Markets
- 3.10 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL ORTHOBIOLOGICS MARKET, BY PRODUCT TYPE

- 5.1 Introduction
- 5.2 Bone Grafts
 - 5.2.1 Autografts
 - 5.2.2 Allografts
 - 5.2.3 Synthetic Bone Grafts
- 5.3 Growth Factors
 - 5.3.1 Bone Morphogenetic Proteins (BMPs)
 - 5.3.2 Platelet-Derived Growth Factor (PDGF)
 - 5.3.3 Vascular Endothelial Growth Factor (VEGF)
 - 5.3.4 Transforming Growth Factor-beta (TGF-?)
 - 5.3.5 Insulin-like Growth Factor (IGF)
- 5.4 Platelet-Rich Plasma (PRP)
- 5.5 Stem Cells
 - 5.5.1 Mesenchymal Stem Cells (MSCs)
 - 5.5.2 Hematopoietic Stem Cells
 - 5.5.3 Induced Pluripotent Stem Cells (iPSCs)
- 5.6 Cell-Based Therapies
 - 5.6.1 Autologous Cell Therapy
 - 5.6.2 Allogeneic Cell Therapy
- 5.7 Other Product Types

6 GLOBAL ORTHOBIOLOGICS MARKET, BY DISTRIBUTION CHANNEL

- 6.1 Introduction
- 6.2 Direct Sales
- 6.3 Indirect Sales
- 6.4 E-Commerce Platforms

7 GLOBAL ORTHOBIOLOGICS MARKET, BY APPLICATION

- 7.1 Introduction
- 7.2 Cervical Fusion
- 7.3 Lumbar Fusion
- 7.4 Thoracic Fusion
- 7.5 Hip Replacement
- 7.6 Shoulder Reconstruction

- 7.7 Dental Implants
- 7.8 Wound Healing
- 7.9 Microfracture Surgery
- 7.10 Ligament Repair
- 7.11 Other Applications

8 GLOBAL ORTHOBIOLOGICS MARKET, BY END USER

- 8.1 Introduction
- 8.2 Hospitals
- 8.3 Ambulatory Surgical Centers
- 8.4 Orthopedic Clinics
- 8.5 Dental Clinics
- 8.6 Rehabilitation Centers
- 8.7 Research Institutes
- 8.8 Other End Users

9 GLOBAL ORTHOBIOLOGICS MARKET, BY GEOGRAPHY

- 9.1 Introduction
- 9.2 North America
 - 9.2.1 US
 - 9.2.2 Canada
 - 9.2.3 Mexico
- 9.3 Europe
 - 9.3.1 Germany
 - 9.3.2 UK
 - 9.3.3 Italy
 - 9.3.4 France
 - 9.3.5 Spain
 - 9.3.6 Rest of Europe
- 9.4 Asia Pacific
 - 9.4.1 Japan
 - 9.4.2 China
 - 9.4.3 India
 - 9.4.4 Australia
 - 9.4.5 New Zealand
 - 9.4.6 South Korea
 - 9.4.7 Rest of Asia Pacific

9.5 South America

9.5.1 Argentina

9.5.2 Brazil

9.5.3 Chile

9.5.4 Rest of South America

9.6 Middle East & Africa

9.6.1 Saudi Arabia

9.6.2 UAE

9.6.3 Qatar

9.6.4 South Africa

9.6.5 Rest of Middle East & Africa

10 KEY DEVELOPMENTS

10.1 Agreements, Partnerships, Collaborations and Joint Ventures

10.2 Acquisitions & Mergers

10.3 New Product Launch

10.4 Expansions

10.5 Other Key Strategies

11 COMPANY PROFILING

11.1 Bioventus LLC

11.2 Nuvasive, Inc.

11.3 Anika Therapeutics, Inc.

11.4 Alphatec Spine, Inc.

11.5 Medtronic plc

11.6 Stryker Corporation

11.7 Globus Medical, Inc.

11.8 Xtant Medical Holdings, Inc.

11.9 Sanofi S.A.

11.10 Orthofix Medical Inc.

11.11 Bone Therapeutics SA

11.11 RTI Surgical, Inc.

11.13 Kuros Biosciences Ltd.

11.14 Smith & Nephew plc

11.15 Integra LifeSciences Holdings Corporation

11.16 Seaspine Holdings Corporation

11.17 Arthrex, Inc.

List Of Tables

LIST OF TABLES

Table 1 Global Orthobiologics Market Outlook, By Region (2024-2032) (\$MN)

Table 2 Global Orthobiologics Market Outlook, By Product Type (2024-2032) (\$MN)

Table 3 Global Orthobiologics Market Outlook, By Bone Grafts (2024-2032) (\$MN)

Table 4 Global Orthobiologics Market Outlook, By Autografts (2024-2032) (\$MN)

Table 5 Global Orthobiologics Market Outlook, By Allografts (2024-2032) (\$MN)

Table 6 Global Orthobiologics Market Outlook, By Synthetic Bone Grafts (2024-2032) (\$MN)

Table 7 Global Orthobiologics Market Outlook, By Growth Factors (2024-2032) (\$MN)

Table 8 Global Orthobiologics Market Outlook, By Bone Morphogenetic Proteins (BMPs) (2024-2032) (\$MN)

Table 9 Global Orthobiologics Market Outlook, By Platelet-Derived Growth Factor (PDGF) (2024-2032) (\$MN)

Table 10 Global Orthobiologics Market Outlook, By Vascular Endothelial Growth Factor (VEGF) (2024-2032) (\$MN)

Table 11 Global Orthobiologics Market Outlook, By Transforming Growth Factor-beta (TGF-?) (2024-2032) (\$MN)

Table 12 Global Orthobiologics Market Outlook, By Insulin-like Growth Factor (IGF) (2024-2032) (\$MN)

Table 13 Global Orthobiologics Market Outlook, By Platelet-Rich Plasma (PRP) (2024-2032) (\$MN)

Table 14 Global Orthobiologics Market Outlook, By Stem Cells (2024-2032) (\$MN)

Table 15 Global Orthobiologics Market Outlook, By Mesenchymal Stem Cells (MSCs) (2024-2032) (\$MN)

Table 16 Global Orthobiologics Market Outlook, By Hematopoietic Stem Cells (2024-2032) (\$MN)

Table 17 Global Orthobiologics Market Outlook, By Induced Pluripotent Stem Cells (iPSCs) (2024-2032) (\$MN)

Table 18 Global Orthobiologics Market Outlook, By Cell-Based Therapies (2024-2032) (\$MN)

Table 19 Global Orthobiologics Market Outlook, By Autologous Cell Therapy (2024-2032) (\$MN)

Table 20 Global Orthobiologics Market Outlook, By Allogeneic Cell Therapy (2024-2032) (\$MN)

Table 21 Global Orthobiologics Market Outlook, By Other Product Types (2024-2032) (\$MN)

Table 22 Global Orthobiologics Market Outlook, By Distribution Channel (2024-2032) (\$MN)

Table 23 Global Orthobiologics Market Outlook, By Direct Sales (2024-2032) (\$MN)

Table 24 Global Orthobiologics Market Outlook, By Indirect Sales (2024-2032) (\$MN)

Table 25 Global Orthobiologics Market Outlook, By E-Commerce Platforms (2024-2032) (\$MN)

Table 26 Global Orthobiologics Market Outlook, By Application (2024-2032) (\$MN)

Table 27 Global Orthobiologics Market Outlook, By Cervical Fusion (2024-2032) (\$MN)

Table 28 Global Orthobiologics Market Outlook, By Lumbar Fusion (2024-2032) (\$MN)

Table 29 Global Orthobiologics Market Outlook, By Thoracic Fusion (2024-2032) (\$MN)

Table 30 Global Orthobiologics Market Outlook, By Hip Replacement (2024-2032) (\$MN)

Table 31 Global Orthobiologics Market Outlook, By Shoulder Reconstruction (2024-2032) (\$MN)

Table 32 Global Orthobiologics Market Outlook, By Dental Implants (2024-2032) (\$MN)

Table 33 Global Orthobiologics Market Outlook, By Wound Healing (2024-2032) (\$MN)

Table 34 Global Orthobiologics Market Outlook, By Microfracture Surgery (2024-2032) (\$MN)

Table 35 Global Orthobiologics Market Outlook, By Ligament Repair (2024-2032) (\$MN)

Table 36 Global Orthobiologics Market Outlook, By Other Applications (2024-2032) (\$MN)

Table 37 Global Orthobiologics Market Outlook, By End User (2024-2032) (\$MN)

Table 38 Global Orthobiologics Market Outlook, By Hospitals (2024-2032) (\$MN)

Table 39 Global Orthobiologics Market Outlook, By Ambulatory Surgical Centers (2024-2032) (\$MN)

Table 40 Global Orthobiologics Market Outlook, By Orthopedic Clinics (2024-2032) (\$MN)

Table 41 Global Orthobiologics Market Outlook, By Dental Clinics (2024-2032) (\$MN)

Table 42 Global Orthobiologics Market Outlook, By Rehabilitation Centers (2024-2032) (\$MN)

Table 43 Global Orthobiologics Market Outlook, By Research Institutes (2024-2032) (\$MN)

Table 44 Global Orthobiologics Market Outlook, By Other End Users (2024-2032) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Orthobiologics Market Forecasts to 2032 – Global Analysis By Product Type (Bone Grafts, Growth Factors, Platelet-Rich Plasma (PRP), Stem Cells, Cell-Based Therapies and Other Product Types), Distribution Channel, Application, End User and By Geography

Product link: <https://marketpublishers.com/r/O23FCD09523AEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O23FCD09523AEN.html>